Akadeum Life Sciences Secures $20M to Boost Cell Therapy Innovations

Akadeum Life Sciences has successfully closed a financing round exceeding $20 million, led by Michigan Capital Network, with participation from Arboretum Ventures and other investors. announced in a press release, this funding will support the company's growth in cell and gene therapy.

The investment comes at a crucial time for Akadeum, following the launch of its GMP-compliant product suite designed for clinical trials. The company has also integrated its microbubble technology into existing cell therapy manufacturing tools, enhancing its appeal to leading biopharma companies.

The funds will be used to scale commercial operations and support customers entering clinical trials. Akadeum's buoyancy-based cell separation technology has gained traction in the industry, with notable interest from partners like Catalent and Charles River Laboratories. The company's platform has shown therapeutic relevance, particularly in preclinical cancer treatment models, and is poised for broader adoption in human cell therapy pipelines.